Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.75%48.58B | 2.16%44.26B | 9.73%12.62B | -0.48%11.19B | -1.92%10.41B | 0.76%10.04B | 3.45%43.32B | 6.76%11.5B | 4.33%11.25B | 4.51%10.61B |
| Cost of revenue | 8.16%29.38B | 1.91%27.16B | 1.61%7.65B | -4.61%6.54B | 0.47%6.4B | 11.40%6.58B | 10.05%26.65B | 15.75%7.53B | 12.23%6.86B | 13.35%6.37B |
| Gross profit | 12.29%19.2B | 2.58%17.1B | 25.11%4.97B | 6.02%4.65B | -5.53%4.01B | -14.70%3.46B | -5.60%16.67B | -6.91%3.97B | -6.04%4.39B | -6.39%4.25B |
| Operating expense | 8.94%14.32B | 1.37%13.14B | 0.73%3.43B | 8.23%3.48B | -5.48%3.11B | 2.19%3.13B | 15.42%12.96B | 20.34%3.4B | 5.61%3.22B | 19.50%3.29B |
| Staff costs | 6.85%3.65B | 8.24%3.41B | ---- | ---- | ---- | ---- | 4.64%3.15B | ---- | ---- | ---- |
| Selling and administrative expenses | 6.21%2.04B | -11.38%1.92B | ---- | ---- | ---- | ---- | 0.14%2.16B | ---- | ---- | ---- |
| -General and administrative expense | 6.21%2.04B | -11.38%1.92B | ---- | ---- | ---- | ---- | 0.14%2.16B | ---- | ---- | ---- |
| Research and development costs | 12.51%5.64B | 1.46%5.01B | ---- | ---- | ---- | ---- | 27.99%4.94B | ---- | ---- | ---- |
| Depreciation and amortization | 29.39%295M | 38.18%228M | ---- | ---- | ---- | ---- | 5.77%165M | ---- | ---- | ---- |
| -Depreciation | 31.02%283M | 41.18%216M | ---- | ---- | ---- | ---- | 5.52%153M | ---- | ---- | ---- |
| -Amortization | 0.00%12M | 0.00%12M | ---- | ---- | ---- | ---- | 9.09%12M | ---- | ---- | ---- |
| Rent and land expenses | -2.46%475M | -3.94%487M | ---- | ---- | ---- | ---- | 14.19%507M | ---- | ---- | ---- |
| Other operating expenses | 6.71%2.23B | 2.36%2.09B | ---- | ---- | ---- | ---- | 27.31%2.04B | ---- | ---- | ---- |
| Operating profit | 23.40%4.88B | 6.83%3.96B | 170.10%1.55B | -0.09%1.17B | -5.71%908M | -66.33%337M | -42.33%3.71B | -60.33%572M | -27.93%1.17B | -46.17%963M |
| Net non-operating interest income (expenses) | 6.38%100M | 23.68%94M | -16.67%25M | -25.00%18M | 60.00%24M | 285.71%27M | 642.86%76M | 1,400.00%30M | 900.00%24M | 350.00%15M |
| Non-operating interest income | 7.10%181M | 32.03%169M | -4.44%43M | -5.26%36M | 62.96%44M | 155.56%46M | 287.88%128M | 221.43%45M | 375.00%38M | 350.00%27M |
| Non-operating interest expense | 8.00%81M | 44.23%75M | 20.00%18M | 28.57%18M | 66.67%20M | 72.73%19M | 10.64%52M | 25.00%15M | 27.27%14M | 0.00%12M |
| Net investment income | -119.65%-113M | 69.12%575M | 561.90%139M | 103.00%6M | -66.20%48M | 1.33%382M | -22.37%340M | -87.04%21M | -217.65%-200M | 1,520.00%142M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 139M | 0 | 3,600.00%37M | 62.50%-3M | 50M | 1M | -8M | |||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | -327.78%-77M | -280.00%-18M | 14.29%-6M | -101.67%-1M | 88.46%-3M | 52.94%-8M | 101.45%10M | 98.79%-7M | 154.55%60M | -2,500.00%-26M |
| Less:Other special charges | 50.00%27M | 280.00%18M | -14.29%6M | 101.67%1M | -88.46%3M | -52.94%8M | -106.37%-10M | -84.78%7M | -154.55%-60M | --26M |
| Less:Write off | --50M | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non-operating income (expenses) | -204.49%-93M | -4.30%89M | -136.36%-4M | -89.83%6M | 828.57%65M | 37.50%22M | 38.81%93M | 266.67%11M | 210.53%59M | -70.83%7M |
| Income before tax | 2.96%4.83B | 9.88%4.69B | 176.96%1.73B | 7.96%1.19B | -12.80%1.01B | -45.09%760M | -31.38%4.27B | -39.26%625M | -34.90%1.11B | -35.56%1.16B |
| Income tax | -73.43%254M | -11.56%956M | 457.69%290M | -41.20%254M | 2.22%184M | -45.32%228M | -25.19%1.08B | -76.79%52M | 24.14%432M | -54.43%180M |
| Net income | 22.48%4.58B | 17.18%3.74B | 151.66%1.44B | 39.47%940M | -15.68%823M | -44.93%532M | -33.26%3.19B | -28.73%573M | -50.11%674M | -30.29%976M |
| Net income continuous operations | 22.50%4.58B | 17.15%3.74B | 151.48%1.44B | 39.47%940M | -15.57%824M | -44.98%532M | -33.25%3.19B | -28.82%573M | -50.11%674M | -30.24%976M |
| Noncontrolling interests | 11.39%1.4B | 30.02%1.26B | 523.81%524M | -15.38%286M | 17.36%284M | -46.36%162M | -36.70%966M | -76.92%84M | 10.46%338M | -50.71%242M |
| Net income attributable to the company | 28.15%3.18B | 11.56%2.48B | 87.53%917M | 94.64%654M | -26.43%540M | -44.43%369M | -31.62%2.22B | 11.39%489M | -67.85%336M | -19.25%734M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 28.15%3.18B | 11.56%2.48B | 87.53%917M | 94.64%654M | -26.43%540M | -44.43%369M | -31.62%2.22B | 11.39%489M | -67.85%336M | -19.25%734M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 27.97%200.04 | 11.40%156.32 | 87.52%57.775 | 94.11%41.23 | -26.57%34 | -44.45%23.315 | -31.66%140.325 | 11.03%30.81 | -67.80%21.24 | -19.34%46.305 |
| Diluted earnings per share | 27.97%200.04 | 11.40%156.32 | 87.51%57.7721 | 94.18%41.2011 | -26.57%34 | -44.45%23.315 | -31.66%140.325 | 11.14%30.81 | -67.83%21.2183 | -19.34%46.305 |
| Dividend per share | 20.00%45 | 15.38%37.5 | 15.38%18.75 | 0 | 15.38%18.75 | 0 | 8.33%32.5 | 8.33%16.25 | 0 | 8.33%16.25 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |